ProfileJobs

GenVec

Suggest Edit
HealthcareTechnologybiotechgeneticspharmaplatformtherapy

GenVec is a clinical-stage biopharmaceutical company focusing on developing a pipeline of therapeutics and vaccines through its proprietary AdenoVerse gene delivery platform. It designs, tests and manufactures adenoviral-based product candidates. The Company’s lead product candidate is CGF166, which is in Phase I, II clinical trial for the treatment of hearing loss and balance disorders.

Revenue(FY, 2016)
$511 K

Employee Rating

3.1More
TypeSubsidiary
Parent CompanyIntrexon
HQGaithersburg, MD, US
Founded1992
Websitegenvec.com
Cybersecurity ratingAMore
GenVec was founded in 1992 and is headquartered in Gaithersburg, MD, US

Viewing summary data as a guest

Sign up for free to see all data

GenVec Office Locations

GenVec has an office in Gaithersburg
Gaithersburg, MD, US (HQ)
910 Clopper Rd #220n
Show all (1)

GenVec Financials and Metrics

Summary Metrics

Founding Date

1992

Total Funding

$2 m

Investors

Canaan Partners
In total, GenVec had raised $2 m. GenVec is a subsidiary of Intrexon

GenVec Revenue

GenVec's revenue was reported to be $511 k in FY, 2016 which is a 42.3% decrease from the previous period.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

17.7m9.4m3.7m6.0m885.0k511.0k

Revenue growth, %

64%(85%)(42%)

General and administrative expense

7.8m9.1m8.5m6.3m4.9m5.2m

R&D expense

17.4m14.3m5.5m2.3m2.6m2.5m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

4.7m4.3m3.2m2.5m2.1m1.2m748.0k1.6m2.1m129.0k252.0k405.0k127.0k193.0k290.0k26.0k173.0k114.0k

General and administrative expense

1.9m2.0m2.0m2.6m2.8m1.9m2.5m2.9m2.4m1.3m1.3m1.3m1.3m999.0k1.4m1.2m1.2m2.7m

R&D expense

4.1m3.8m4.3m3.6m3.4m2.4m1.4m1.6m698.0k480.0k523.0k648.0k675.0k705.0k737.0k568.0k522.0k767.0k

Operating expense total

6.0m5.8m6.4m6.2m6.2m4.3m3.9m4.5m3.1m1.8m1.9m1.9m2.0m1.7m2.1m1.7m1.7m3.4m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

4.1m4.2m5.2m8.0m7.0m3.7m

Accounts Receivable

2.4m947.0k201.0k325.0k166.0k22.0k

Prepaid Expenses

230.0k226.0k337.0k219.0k245.0k

Inventories

Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

4.7m8.7m2.8m4.1m5.0m4.0m5.8m5.0m15.2m5.1m4.0m7.2m6.7m6.6m6.3m9.6m4.9m2.5m

Accounts Receivable

2.7m2.7m1.7m1.4m991.0k772.0k652.0k264.0k2.2m159.0k321.0k427.0k281.0k263.0k140.0k49.0k176.0k84.0k

Prepaid Expenses

409.0k352.0k268.0k474.0k311.0k476.0k1.1m211.0k187.0k397.0k293.0k244.0k455.0k339.0k249.0k519.0k369.0k224.0k

Current Assets

33.7m31.5m26.1m22.9m19.5m13.0m11.1m7.6m17.6m15.1m13.4m13.3m11.8m10.5m7.3m10.2m8.9m4.6m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(7.4m)(14.1m)(10.0m)(2.5m)(6.5m)(5.8m)

Depreciation and Amortization

234.0k242.0k174.0k220.0k97.0k90.0k

Accounts Payable

(1.7m)202.0k

Cash From Operating Activities

(8.4m)(10.8m)(9.3m)(2.0m)(5.9m)(6.0m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(3.5m)(4.9m)(3.2m)(6.9m)(10.9m)(3.0m)(6.2m)(9.1m)(963.0k)(2.6m)(4.2m)(1.5m)(3.4m)(4.9m)(1.9m)(3.1m)(4.3m)(4.3m)

Depreciation and Amortization

110.0k175.0k56.0k119.0k181.0k49.0k96.0k139.0k100.0k130.0k197.0k23.0k47.0k72.0k26.0k48.0k70.0k23.0k

Accounts Payable

(1.1m)(1.8m)19.0k308.0k653.0k(883.0k)

Cash From Operating Activities

(4.5m)(6.5m)(2.0m)(5.2m)(8.0m)(3.3m)(5.6m)(7.8m)(1.6m)(2.2m)(4.0m)(2.0m)(3.6m)(4.7m)(1.8m)(3.6m)(4.8m)(2.8m)
show all
USDQ2, 2011

Financial Leverage

1.2 x
Show all financial metrics

GenVec Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

Learn more about our premium products
SecurityScorecard logo

GenVec Online and Social Media Presence

GenVec's Trends

Embed Graph

GenVec News and Updates

January 08, 2019

Malaria Vaccines Market Insights with Key Players GlaxoSmithKline, Sanaria, Nobelpharma, Sumaya Biotech and GenVec and Forecast to 2023

Pregnant women and unborn children cannot escape from aftermaths of malaria. It is reported that malaria-affected pregnant women give premature birth or sometimes give birth to dead infants. Posted via Industry Today. Follow us on Twitter @IndustryToday
November 24, 2018

Global Malaria Vaccines Market 2018 Analysis By Companies like GlaxoSmithKline plc, Sanaria Inc., Nobelpharma Co., Ltd., Sumaya Biotech and GenVec Inc.

Summary This report includes market status and forecast of global and major regions, with the introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Posted via Industry Today. Follow us on Twitter @Indu…

 GenVec Frequently Asked Questions

  • When was GenVec founded?

    GenVec was founded in 1992.

  • How many employees does GenVec have?

    GenVec has 31 employees.

  • What is GenVec revenue?

    Latest GenVec annual revenue is $511 k.

  • What is GenVec revenue per employee?

    Latest GenVec revenue per employee is $16.5 k.

  • Who are GenVec competitors?

    Competitors of GenVec include Cell Therapies, Andros Pharmaceuticals and Haplogen.

  • Where is GenVec headquarters?

    GenVec headquarters is located at 910 Clopper Rd #220n, Gaithersburg.

  • Where are GenVec offices?

    GenVec has an office in Gaithersburg.

  • How many offices does GenVec have?

    GenVec has 1 office.